Spondylarthritis presenting with an allergic immediate systemic reaction to adalimumab in a woman: A case report

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Benucci, Maurizio ^a   Manfredi, Mariangela ^a   Testi, Sergio ^a   Iorno, Maria L ^a   Valentini, Maurizio ^a   Soldaini, Francesca ^a   Campi, Paolo ^a  

^a Nuovo Ospedale S Giovanni di Dio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ATENOLOL; CHLORTALIDONE; CORTICOSTEROID; DEFLAZACORT; IMMUNOGLOBULIN E; LEFLUNOMIDE; LEVOTHYROXINE; MANNITOL; POLYSORBATE 80; SALAZOSULFAPYRIDINE; VALSARTAN;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; CASE REPORT; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEEL PAIN; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMOBILIZATION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INTRACUTANEOUS TEST; ISCHIALGIA; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATCH TEST; PRICK TEST; PRIORITY JOURNAL; SACROILIITIS; SKIN TEST; SPONDYLARTHRITIS; THYROID NODULE; TREATMENT RESPONSE; URTICARIA; VISUAL DISORDER; X RAY;

EID: 79955111994     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-155     Document Type: Article

References (15)

1. Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. ME Weinblatt EC Keystone DE Furst LW Moreland MH Weisman CA Birbara LA Teoh SA Fischkoff EK Chartash, Arthritis Rheum 2003 48 35 45 10.1002/art.10697 12528101 (Pubitemid 36091645)
2. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. PJ Mease DD Gladman CT Ritchlin EM Ruderman SD Steinfeld EH Choy JT Sharp PA Ory RJ Perdock MA Weinberg, Arthritis Rheum 2005 52 3279 3289 10.1002/art.21306 16200601 (Pubitemid 41447111)
3. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). GT Ho A Mowat L Potts A Cahill C Mowat CW Lees NC Hare JA Wilson R Boulton-Jones M Priest DA Watts AG Shand ID Arnott RK Russell DC Wilson AJ Morris J Satsangi, Aliment Pharmacol Ther 2009 29 527 534 10.1111/j.1365-2036.2008.03919.x 19183339
4. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab. D Snchez-Cano JL Callejas-Rubio N Ortego-Centeno R Ruiz-Villaverde, Clin Exp Rheumatol 2006 24 5 Suppl 42 128 17067448
5. Adalimumab-induced urticaria. SJ George HL Anderson S Hsu, Dermatol Online J 2006 12 4 17459290
6. Urticaria and angioedema-like skin reactions in a patient treated with adalimumab. SN Nikas PV Voulgari AA Drosos, Clin Rheumatol 2007 26 787 788 10.1007/s10067-005-0197-7 16421645 (Pubitemid 46554095)
7. Acute generalized skin eruption due to adalimumab: report of two cases. J Dalmau E Roé F Corella X García-Navarro L Peramiquel A Alomar, J Eur Acad Dermatol Venereol 2007 21 1105 1106 10.1111/j.1468-3083.2007.02089.x 17714134 (Pubitemid 47304614)
8. Adalimumab-induced urticaria in Spanish. S Mallo J Santos-Juanes, Actas Dermosifiliogr 2007 98 511 512 10.1016/S0001-7310(07)70124-2 17669313
9. Successful adalimumab desensitization after generalized urticaria and rhinitis. B Rodrguez-Jiménez J Domnguez-Ortega C Gonzlez-Herrada C Kindelan-Recarte P Loribo-Bueno N Garrido-Pẽo, J Invest Allergol Clin Immunol 2009 19 246 247
10. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. K Brockow A Romano M Blanca J Ring W Pichler P Demoly, Allergy 2002 57 45 51 12144555 (Pubitemid 34146185)
11. Injection site reactions to TNF- blocking agents with positive skin tests. M Benucci M Manfredi P Demoly P Campi, Allergy 2008 63 138 139 18053024 (Pubitemid 350198239)
12. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. M Paltiel LM Gober A Deng J Mikdashi I Alexeeva SS Saini AA Gaspari, Arch Dermatol 2008 144 1190 1194 10.1001/archderm.144.9.1190 18794465
13. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor- antagonists. P Campi M Benucci M Manfredi P Demoly, Curr Opin Allergy Clin Immunol 2007 7 393 403 17873578 (Pubitemid 47415282)
14. Adverse side effects to biological agents. WJ Pichler P Campi, Drug Hypersensitivity Basel: Karger, Pichler WJ, 2007 160 174
15. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. FD Finkelman ME Rothenberg EB Brandt SC Morris RT Strait, J Allergy Clin Immunol 2005 115 449 458 10.1016/j.jaci.2004.12.1125 15753886